Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Myosin light chain 1, skeletal muscle isoform (MYL1) is a non-regulatory “essential” (alkali) light chain expressed predominantly in fast skeletal muscle[1][3][7]. It is part of the myosin hexameric complex: two heavy chains, two essential (alkali) light chains, and two regulatory light chains[1][3][4]. MYL1 binds to the IQ1 motif on the myosin heavy chain neck region, stabilizing the structure and contributing to muscle contraction by modulating the ATPase activity of the entire complex[4][6]. MYL1 is necessary for proper muscle fiber formation and maintenance[1][7]; defects in MYL1 can lead to congenital myopathies characterized by muscle weakness and structural abnormalities[1][5]. As a member of the EF-hand family, it contains calcium-binding motifs but is classified as non-regulatory, with its function focused on structural integrity and modulation of force rather than direct signal transduction[4][6]. There are no drugs that specifically target MYL1, and it is not considered a conventional therapeutic target like a receptor or enzyme[1][4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Myosin light chain 1, skeletal muscle isoform (MYL1).